Special Issue

Antivirals and Targets to Fight RNA Viruses

Message from the Guest Editors

From a general point of view, RNA virus cycles share some common stages that include virus entry, translation, replication, assembly and release. These processes have been traditionally chosen to fight viral infections using vaccines, antibodies or chemical inhibitors that interfere with the function of cellular and/or viral proteins. However, these strategies usually fail in their goal due to the emergence of resistant variants. Therefore, the identification of new molecular targets is a main goal in the field. This Special Issue aims to provide an updated overview of current antiviral strategies, their potential limitations and how they can be improved in the near future. Original manuscripts and review articles focused on the identification of new viral and cellular targets that may be useful against infections caused by different RNA viruses, thus facilitating the development of new generic antiviral strategies, are also welcome. Finally, reports on further medical and biotechnological strategies using newly identified viral targets and antiviral compounds will also be considered.

Guest Editors

Dr. Cristina Romero-López

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av. Conocimiento, Armilla, 18016 Granada, Spain

Dr. Alfredo Berzal-Herranz

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN) CSIC, Granada, Spain

Deadline for manuscript submissions

closed (24 January 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/178029

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

